A prospective, multicentre, randomised, open‐label, 2-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with docetaxel or in combination with gemcitabine in the treatment of patients with metastatic non-small cell lung cancer in progression after first line treatment.

Trial Profile

A prospective, multicentre, randomised, open‐label, 2-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with docetaxel or in combination with gemcitabine in the treatment of patients with metastatic non-small cell lung cancer in progression after first line treatment.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Masitinib (Primary) ; Docetaxel; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 According to an AB Science media release, this study did not pass the pre-planned statistical analysis to detect a superiority trend in overall survival between masitinib in combination with standard-of-care chemotherapy when compared against its relevant historical meta-analysis benchmark. Therefore, the indication will not be moved to phase III.
    • 25 Jun 2015 Status changed from recruiting to completed, according to an AB Science media release.
    • 05 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top